Venmax Drugs and Pharmaceuticals Limited has intimated the Bombay Stock Exchange about an upcoming Board of Directors meeting scheduled for Thursday, November 12, 2026 at 3:00 PM. The primary agenda of the meeting is to consider and approve the company's Unaudited Financial Results for the quarter ended September 30, 2026.
The company also disclosed that the trading window for dealing in securities of the company remains closed for all designated persons. The trading window closure began on October 1, 2026 and will continue until November 14, 2026, which represents 48 hours after the anticipated approval of the unaudited standalone financial results for Q2 FY27.
This disclosure is made in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was digitally signed by Priyanka Agarwal, Company Secretary & Compliance Officer, on November 5, 2026 at 16:30:44 IST.